@windhamvp

First Patient Enrolled in Novocure’s Phase 3 Pivotal LUNAR Trial Testing Tumor Treating Fields for the Treatment of Advanced Non-Small Cell Lung Cancer After Failing Platinum-Based Therapy

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NVCR) announced today that the first patient has been enrolled in LUNAR, its phase 3 pivotal trial of Tumor Treating Fields at 150 kHz as … Continued

Personal Genome Diagnostics Launches CancerSELECT™ 125 Test for Pan-Cancer Tumor Profiling –Identifies Tumor-Specific, Clinically Actionable Genetic Alterations to Inform Treatment Decisions with Unparalleled Accuracy

BALTIMORE / PRNewswire/ — Personal Genome Diagnostics Inc. (PGDx), a leading provider of advanced cancer genome testing products and services, today announced the launch of its CancerSELECT™ 125 test for pan-cancer … Continued

Novocure’s Optune® (NovoTTF-100A) Approved in Japan for the Treatment of Newly Diagnosed Glioblastoma

Optune is the first MHLW-approved therapy in more than a decade to demonstrate statistically and clinically significant extension of survival in newly diagnosed GBM patients HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) … Continued

Long-Term Analysis of All 695 Patients Enrolled in Novocure’s Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Confirms Successful Interim Analysis Results and Demonstrates Superior Two- and Four-Year Survival Rates

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NVCR) announced today that a long-term analysis of the full trial cohort from its phase 3 pivotal EF-14 trial of Optune® in combination with temozolomide for … Continued

United Healthcare Issues Positive Coverage Decision for Optune

Novocure NVCR announced today that United Healthcare will cover Optune as an adjunctive therapy for the treatment of glioblastoma (GBM) when used according to FDA labeled indications and contraindications, effective … Continued